ASP Isotopes (ASPI) investor relations material

Executive summary

• Completed the acquisition of Renergen, expanding into helium and LNG production in South Africa, and deconsolidated Skyline, focusing on core segments: nuclear fuels, specialist isotopes, and helium/LNG.

• Revenue for Q1 2026 was $4.2M, up from $1.1M in Q1 2025, driven by radiopharmacy and LNG sales.

• Net loss from continuing operations was $26.7M, compared to $8.5M in Q1 2025, reflecting higher R&D and SG&A expenses due to acquisitions and expansion.

• Cash and cash equivalents stood at $207.3M, with short-term investments of $83.2M as of March 31, 2026.

Financial highlights

• Gross profit increased to $1.7M from $0.3M year-over-year, with gross margin improvement due to higher sales volume.

• Research and development expenses rose to $5.3M from $1.5M, reflecting increased headcount and facility costs.

• Selling, general and administrative expenses surged to $21.3M from $6.7M, mainly due to integration of Renergen and ECNP.

• Interest income was $3.0M, offset by $1.7M in interest expense and a $3.7M foreign exchange loss.

• Net cash used in operating activities was $17.8M; investing activities used $97.2M, mainly for acquisitions and investments.

Outlook and guidance

• Initial commercial shipments of enriched C-14 and Si-28 targeted for mid-to-late 2026; Yb-176 shipments expected in Q3 2026.

• Expansion plans for additional isotope enrichment plants in South Africa, Iceland, and the US.

• Sufficient liquidity to fund operations for at least 12 months, but additional capital may be needed for large-scale projects like Phase 2 of the Virginia Gas Project.